Table 3. “Relatively dominant” epitopes.
| peptide name in the figures | gene name and (a.a. position) | restricting allele | recognized by | Temporal Expression |
|---|---|---|---|---|
| A1H6 | C10L (298–306) | A1 supertype | 42% (5/12) of A*0101 (+) donors | early |
| A1H7 | C12L (326–334) | A*2902 | 100% (2/2) of A*2902 (+) donors | early |
| A2H12 | G5R (18–26) | A2 supertype | 58% (7/12) of A*0201 (+) donors | immediate-early |
| A2H8 | E2L (249–257) | A2 supertype | 42% (5/12) of A*0201 (+) donors | early |
| A2H6 | B22R/C16L (60-68) | A*0201 | 33% (4/12) of A*0201 (+) donors | ?a |
| A2H7 | C7L (74–82) | A*0201 | 25% (3/12) of A*0201 (+) donors | early |
| A2H10 | F12L (286–295) | A2 supertype | 25% (3/12) of A*0201 (+) donors | early |
| A3H1 | A8R (79–88) | A3 supertype | 36% (4/11) of A*0301 (+) donors | immediate-early |
| A24H4 | D5R (349–357) | A24 supertype | 44% (4/9) of A*2402 (+) donors | early |
| A24H1 | A48R (58–66) | A*2301 | 33% (3/9) of A*2402 (+) donors | immediate-early |
| B7H6 | J6R (303-311) | B7 or B7 supertype | 25% (2/8) of B*0702 (+) donors | early |
| B44H7 | D1R (126–134) | B*4403 | 67% (2/3) of B*1801 (+) donors | early |
| A1H2 | B8R (139–147) | A1 supertype | 46% of VACV-specific cells of A*2902 & A*3001 (+) donor | early |
| A2H10 | F12L (286–295) | A2 supertype | 38% of VACV-specific cells of A*0295 (+) donorb | |
| A2H6 | B22R/C16L (60-68) | A*0201 | 36% of VACV-specific cells of A*0201 (+) donor | |
| A2H12 | E2L (249–257) | A2 supertype | 25% of VACV-specific cells of A*0201 (+) donor | |
| 21% of VACV-specific cells of A*0295 (+) donorb | ||||
| A2H8 | G5R (18–26) | A2 supertype | 22% of VACV-specific cells of A*0201 (+) donor | |
| A3H1 | I3L (116–124) | A3 & A*1101 | 26% of VACV-specific cells of A*0301 (+) donor | immediate-early |
| A24H1 | A48R (58–66) | A*2301 | 31% of VACV-specific cells of A*2402 (+) donor | |
| B7H5 | J2R (62-70) | B*3502 | 236% of VACV-specific cells of B*3503 (+) donor | early |
| B7H7 | O1L (335–344) | B7 supertype | 129% of VACV-specific cells of B*3503 (+) donor | immediate-early |
| B7H1 | B22R/C16L (53-61) | B7 | 32% of VACV-specific cells of B*0723 (+) donor | ?a |
| B44H7 | D1R (126–134) | B*4403 | 27% of VACV-specific cells of B*1801 (+) donor |
a
: B22R/C16L was not analyzed
b
: HLA supertype asignment of A*0295 has not yet been determined.